Year-end Sale % OFF 
Abstract
To evaluate the diagnostic value of 18F-FDG PET/CT for detection of bone metastasis in comparison with the efficacies of 18F-FDG PET/CT, CT, 18F-FDG PET and conventional planar bone scintigraphy in a series of cancer patients. Five hundred and thirty patients who underwent both 18F-FDG PET/CT and bone scintigraphy within 1 month were retrospectively analyzed. The skeletal system was classified into 10 anatomic segments and interpreted blindly and separately. For each modality, the sensitivity, specificity, accuracy, PPV and NPV were calculated and the results were statistically analyzed. Bone metastases were confirmed in 117 patients with 459 positive segments. On patient-based analysis, the sensitivity, specificity, accuracy, PPV and NPV of 18F-FDG PET/CT were significantly higher than bone scintigraphy, CT and 18F-FDG PET (P<0.05). On segment-based analysis, the sensitivity of CT, bone scintigraphy, 18F-FDG PET and 18F-FDG PET/CT were 70.4%, 89.5%, 89.1% and 97.8%, respectively (P<0.05, compared with 18F-FDG PET/CT). The overall specificity and accuracy of the four modalities were 89.1%, 91.8%, 90.3%, 98.2% and 90.3%, 90.9%, 89.8%, 98.0%, respectively (P<0.05, compared with 18F-FDG PET/CT). The PPV and NPV were 89.8%, 87.6%, 85.6%, 97.2% and 85.6%, 93.2%, 92.8%, 98.6%, respectively. Three hundred and twelve lesions or segments were presented as lytic or sclerotic changes on CT images at the corresponding sites of increased 18F-FDG uptake. In lytic or mixed lesions, the sensitivity of 18F-FDG PET/CT and 18F-FDG PET were better than bone scintigraphy, while in osteoblastic lesions bone scintigraphy had a similar performance with 18F-FDG PET/CT but better than 18F-FDG PET alone. Our data allow the conclusion that 18F-FDG PET/CT is superior to planar bone scintigraphy, CT or 18F-FDG PET in detecting bone metastasis. 18F-FDG PET/CT may enhance our diagnosis of tumor bone metastasis and provide more information for cancer treatment.
Highlights
Diagnostic images have played notable roles in bone metastasis detection of malignancy, such as radiography, planar bone scintigraphy (BS), single photon emission computed tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and recently PET/CT (Rybak et al, 2001)
In lytic or mixed lesions, the sensitivity of 18F-FDG PET/CT and 18F-FDG PET were better than bone scintigraphy, while in osteoblastic lesions bone scintigraphy had a similar performance with 18F-FDG PET/CT but better than 18F-FDG PET alone
Our data allow the conclusion that 18F-FDG PET/CT is superior to planar bone scintigraphy, CT or 18F-FDG PET in detecting bone metastasis. 18F-FDG PET/CT may enhance our diagnosis of tumor bone metastasis and provide more information for cancer treatment
Summary
Diagnostic images have played notable roles in bone metastasis detection of malignancy, such as radiography, planar bone scintigraphy (BS), single photon emission computed tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and recently PET/CT (Rybak et al, 2001). Metastasis lesions may be missed because the sensitivity of BS relies on the identification of osteoblastic reaction rather than the detection of the tumor cells. As the most widely accepted metabolic imaging modality, 18F-deoxyglucose (FDG) PET demonstrates apparent advantages in providing information with regard to metastasis localizations both in soft tissue and skeletal (Fogelman et al, 2005). With tracer accumulation 18F-FDG PET visualizes regions of enhanced metabolic activity and complements other imaging modalities based on structural anatomic changes (Wu et al, 2013). With tracer accumulation 18F-FDG PET visualizes regions of enhanced metabolic activity and complements other imaging modalities based on structural anatomic changes (Wu et al, 2013). 18F-FDG PET had a better performance in esophagus, thyroid, nasopharyngeal and lung carcinoma (Kato et al, 2005; Shinji et al, 2007; Liu et al, 2010; Chang et al, 2013)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
